Cellectricon Announces World's First System for High Throughput RNAi Screening |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Cellectricon AB
Fabriksgatan 7
Goteborg, 412 50
Sweden
Press release date: September 12, 2007
Cellectricon Announces World's First System for High Throughput RNAi Screening
GOTHENBURG, Sweden, September 12/ / -- Cellectricon, a leading provider of miniaturized & cell-based screening solutions for drug discovery, today announced collaboration with EPFL (Ecole Polytechnique Federale de Lausanne, Switzerland). EPFL is evaluating Cellectricon's next-generation high throughput electroporation system. Cellaxess-HT is the world's first high throughput electroporation system tailor-made for genome wide RNAi screening and will be launched Q2 2008.
"We are pleased to collaborate with EPFL and look forward to bringing this state-of-the-art system to the market." says Dr. Mattias Karlsson, CEO at Cellectricon. "Cellaxess-HT will be the first of its kind on the market and will significantly impact drug discovery by opening the door to using more biologically relevant cell types in genome wide RNAi screening."
"We are impressed by the unprecedented high throughput delivery of genetic materials the Cellaxess-HT system offers. We believe that Cellaxess-HT has the potential to greatly advance our efforts in our RNAi research programs", says Dr. Gerardo Turcatti, Director of the Biomolecular Screening Facility at EPFL, Lausanne, Switzerland.
About the Cellaxess-HT system
Cellaxess-HT addresses the critical need for high throughput delivery of genetic materials to hard to transfect cells in several cell-based screening assays. Cellaxess-HT will be the only fully automated system on the market allowing for high throughput electroporation of cells in culture directly in 384-well microplates. The throughput for the system is up to 50,000 wells per day and allows for genome wide screening with high transfection efficiencies and viabilities in cell lines as well as primary cell types.
About Cellectricon
Cellectricon invents and develops new types of functional cell-based screening systems for applications in drug discovery and basic research. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products are designed to enable substantial increases in productivity at the highest data quality.
Source: Cellectricon AB
Contact Details: Susanne Fagerlund, VP Market Communications, Phone: +46-(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com
|
|
|
|
|
See related product stories
|
|
|
|
|
|
|
|
|
|
